Knockdown of NEIL3 inhibits the growth of breast cancer cells by mediating the PI3K/Akt/mTOR axis

Background: To explore the role of Nei endonuclease VIII-like 3 (NEIL3) in breast cancer (BC) cell proliferation and motility and its underlying mechanism. Methods: BC cell lines were analyzed. NEIL3 expression levels in BC tissues was assessed using the UALCAN and Kaplan-Meier Plotter databases. NEIL3 knockdown was performed using siRNAs, and its effects on cell growth, motility, Epithelial-Mesenchymal Transition (EMT) markers, and the Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/Akt/mTOR) axis were evaluated using Immunoblotting, cell counting kit-8 (CCK-8) assays, colony formation, Transwell as well as wound healing assays. Results: NEIL3 was highly expressed in BC tissues and cell lines. NEIL3 knockdown inhibited cell growth, motility and reduced EMT marker expression. It also decreased phosphorylation levels of proteins, indicating inhibition of the PI3K/Akt/mTOR axis. Conclusions: NEIL3 mediates BC cell proliferation as well as motility by activating the PI3K/Akt/mTOR axis. Targeting NEIL3 may offer a new approach to combat BC.

NEIL3; BC; PI3K/Akt/mTOR axis; Growth; Motility; EMT

[1] Hu D, Zhuo W, Gong P, Ji F, Zhang X, Chen Y, et al. Biological differences between normal and cancer-associated fibroblasts in breast cancer. Heliyon. 2023; 9: e19803.

[2] Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: biology, biomarkers, and treatments. International Immunopharmacology. 2020; 84: 106535.

[3] Kaboli PJ, Imani S, Jomhori M, Ling KH. Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy. American Journal of Cancer Research. 2021; 11: 5155–5183.

[4] Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nature Communications. 2021; 12: 1786.

[5] Wang M, Wu Y, Li X, Dai M, Li S. IGJ suppresses breast cancer growth and metastasis by inhibiting EMT via the NF‑κB signaling pathway. International Journal of Oncology. 2023; 63: 105.

[6] Dickinson K, Hammond L, Akpa M, Chu LL, Lalonde CT, Goumba A, et al. WT1 regulates expression of DNA repair gene Neil3 during nephrogenesis. American Journal of Physiology. Renal Physiology. 2023; 324: F245–F255.

[7] Lai HH, Hung LY, Yen CJ, Hung HC, Chen RY, Ku YC, et al. NEIL3 promotes hepatoma epithelial-mesenchymal transition by activating the BRAF/MEK/ERK/TWIST signaling pathway. The Journal of Pathology. 2022; 258: 339–352.

[8] Wang W, Yin Q, Guo S, Wang J. NEIL3 contributes toward the carcinogenesis of liver cancer and regulates PI3K/Akt/mTOR signaling. Experimental and Therapeutic Medicine. 2021; 22: 1053.

[9] Huang H, Hua Q. NEIL3 mediates lung cancer progression and modulates PI3K/AKT/mTOR signaling: a potential therapeutic target. International Journal of Genomics. 2022; 2022: 8348499.

[10] Zhao C, Liu J, Zhou H, Qian X, Sun H, Chen X, et al. NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma. Cancer Cell International. 2021; 21: 228.

[11] Sun X, Liu P. Prognostic biomarker NEIL3 and its association with immune infiltration in renal clear cell carcinoma. Frontiers in Oncology. 2023; 13: 1073941.

[12] Zhang M, Jiang Y, Wang J, Yue Y, Liu W, Wang L, et al. NEIL3 promotes cell proliferation of ccRCC via the cyclin D1-Rb-E2F1 feedback loop regulation. DNA Repair. 2024; 133: 103604.

[13] Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Seminars in Cancer Biology. 2019; 59: 125–132.

[14] Varshney P, Saini N. PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2018; 1864: 1795–1803.

[15] Yang Z, Zhang C, Liu X, Che N, Feng Y, Xuan Y. SETD5 regulates glycolysis in breast cancer stem-like cells and fuels tumor growth. The American Journal of Pathology. 2022; 192: 712–721.

[16] Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annual Review of Pathology. 2022; 17: 181–204.

[17] Li Z, Liu B, Li C, Sun S, Zhang H, Sun S, et al. NRBP2 functions as a tumor suppressor and inhibits epithelial-to-mesenchymal transition in breast cancer. Frontiers in Oncology. 2021; 11: 634026.

[18] Patel JR, Banjara B, Ohemeng A, Davidson AM, Boue SM, Burow ME, et al. Novel therapeutic combination targets the growth of letrozole-resistant breast cancer through decreased cyclin B1. Nutrients. 2023; 15: 1632.

[19] Yang H, Liu D, Wang YP. Physalin A exerts neuroprotective effects: inhibition of OGD/R-induced cellular pyroptosis and inflammatory responses in nerve cells. Signa Vitae. 2023; 19: 168–174.

[20] Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers in Oncology. 2014; 4: 64.

[21] Gao Z, Wu J, Wu X, Zheng J, Ou Y. SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis. Open Medicine. 2020; 15: 1072–1082.

[22] Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR axis as a therapeutic target in endometrial cancer. Clinical Cancer Research. 2012; 18: 5856–5864.

[23] Lou C, Xu X, Chen Y, Zhao H. Alisol A suppresses proliferation, migration, and invasion in human breast cancer MDA-MB-231 Cells. Molecules. 2019; 24: 3651.

[24] Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database of Systematic Reviews. 2019; 10: CD012160.